250 related articles for article (PubMed ID: 27741937)
1. Alopecia universalis as a side effect of pegylated interferon α-ribavirin combination therapy for hepatitis C: a rare case report.
Verma P; Dayal S; Jain VK; Amrani A
J Chemother; 2017 Dec; 29(6):380-382. PubMed ID: 27741937
[TBL] [Abstract][Full Text] [Related]
2. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
Demirturk N; Aykin N; Demirdal T; Cevik F
Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
[No Abstract] [Full Text] [Related]
3. Managing adverse effects of interferon-alfa and ribavirin in combination therapy for HCV.
Slim J; Afridi MS
Infect Dis Clin North Am; 2012 Dec; 26(4):917-29. PubMed ID: 23083824
[TBL] [Abstract][Full Text] [Related]
4. Taste disturbances during therapy with pegylated interferon-alpha 2b and ribavirin in patients with chronic hepatitis C.
Klimacka-Nawrot E; Musialik J; Suchecka W; Petelenz M; Hartman M; Lichtański P; Błońska-Fajfrowska B
Wiad Lek; 2010; 63(4):289-99. PubMed ID: 21608370
[TBL] [Abstract][Full Text] [Related]
5. [Side effects of interferon-based therapy for chronic hepatitis C virus infection and clinical management of them].
Iwasaki Y; Ikeda F; Yamamoto K
Nihon Rinsho; 2011 May; 69 Suppl 4():215-20. PubMed ID: 22096922
[No Abstract] [Full Text] [Related]
6. Unilateral hearing loss due to pegylated interferon-α2b and ribavirin therapy.
Jain S; Midha V; Sood A
Indian J Gastroenterol; 2011 Sep; 30(5):239-40. PubMed ID: 21986854
[No Abstract] [Full Text] [Related]
7. A case of irreversible leukoencephalopathy in a patient with C virus hepatitis treated with pegylated interferon-alpha-2b and ribavirin.
Iacob SA; Petrescu AM; Iacob DG
Rom J Intern Med; 2013; 51(3-4):197-200. PubMed ID: 24620633
[TBL] [Abstract][Full Text] [Related]
8. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
Kartal ED; Alpat SN; Ozgunes I; Usluer G
Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):817-20. PubMed ID: 17700271
[TBL] [Abstract][Full Text] [Related]
9. [Pegylated intereferon hematological safety in comparison with standard].
Fazylov VKh; Manapova ÉR; Tkacheva SV; Sozinova IuM
Eksp Klin Gastroenterol; 2012; (6):96-9. PubMed ID: 23402198
[TBL] [Abstract][Full Text] [Related]
10. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
Hunyady B; Kovács B; Battyáni Z
Orv Hetil; 2011 Dec; 152(50):1997-2009. PubMed ID: 22112373
[TBL] [Abstract][Full Text] [Related]
11. Summaries for patients. Pegylated interferon with or without ribavirin for patients with hepatitis C receiving hemodialysis.
Ann Intern Med; 2013 Dec; 159(11):I-14. PubMed ID: 24297207
[No Abstract] [Full Text] [Related]
12. [Cutaneous sarcoidosis after treatment with interferon for hepatitis C: A not entirely rare but often overlooked reaction].
Waltschew A
Pathologe; 2016 Mar; 37(2):184-6. PubMed ID: 26769217
[TBL] [Abstract][Full Text] [Related]
13. Alopecia universalis after discontinuation of pegylated interferon and ribavirin combination therapy for hepatitis C: a case report.
Gamal N; Brodosi L; Misciali C; Patrizi A; Vukatana G; Malavolta N; Bernardi M; Andreone P
Ann Hepatol; 2014; 13(2):293-6. PubMed ID: 24558223
[TBL] [Abstract][Full Text] [Related]
14. Exacerbation of alopecia areata during pegylated interferon alpha-2b and ribavirin therapy, possibly due to the collapse of hair follicle immune privilege.
Ito T; Suzuki T; Funakoshi A; Tokura Y
Eur J Dermatol; 2014; 24(5):631-3. PubMed ID: 25115439
[No Abstract] [Full Text] [Related]
15. Pegylated interferon (alone or with ribavirin) for chronic hepatitis C in haemodialysis population.
Espinosa M; Hernàndez J; Arenas MD; Carnicer F; Caramelo C; Fabrizi F
Kidney Blood Press Res; 2015; 40(3):258-65. PubMed ID: 25997572
[TBL] [Abstract][Full Text] [Related]
16. [Development of sarcoidosis during treatment for chronic hepatitis C with pegylated interferon alfa-2a and ribavirin: case report and literature review].
Cacopardo B; Pinzone MR; Nunnari G
Infez Med; 2013 Mar; 21(1):40-44. PubMed ID: 23524900
[TBL] [Abstract][Full Text] [Related]
17. Is combination therapy interferon and ribavirin in patients with chronic hepatitis C infection toxic for eyes?
Mousa N; Besheer T; Gad Y; Elbendary A; Mokbel T; Abdel-Aziz A
J Ocul Pharmacol Ther; 2013 Apr; 29(3):345-8. PubMed ID: 23113644
[TBL] [Abstract][Full Text] [Related]
18. [Pegylated interferon and ribavirin associated retinopathy in patients with hepatitis C].
Burgueño-Montañés C; Pérez-Álvarez R
Arch Soc Esp Oftalmol; 2011 Jun; 86(6):193-5. PubMed ID: 21767697
[TBL] [Abstract][Full Text] [Related]
19. [Autoimmune hemolytic anemia in a case of chronic hepatitis type C 56 weeks after initiation of second line treatment with pegylated interferon alpha2b/ribavirin combination therapy].
Nishino R; Ikeda N; Unoura M
Nihon Shokakibyo Gakkai Zasshi; 2011 Sep; 108(9):1571-8. PubMed ID: 21891998
[TBL] [Abstract][Full Text] [Related]
20. Severe autoimmune hemolytic anemia in a patient with chronic hepatitis C during treatment with Peg interferon alfa-2a and ribavirin.
Ennaifer R; Cheikh M; Romdhane H; Hefaiedh R; Ben Nejma H; Bel Hadj N
Tunis Med; 2014 Jan; 92(1):42-3. PubMed ID: 24879173
[No Abstract] [Full Text] [Related]
[Next] [New Search]
